Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Verve Therapeutics, Inc. - Common Stock
(NQ:
VERV
)
11.13
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jul 24, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Verve Therapeutics, Inc. - Common Stock
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
↗
November 08, 2022
Gainers
Via
Benzinga
Dow Surges 400 Points; Crude Oil Down 1%
↗
November 07, 2022
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 400 points on Monday.
Via
Benzinga
Why Verve Therapeutics' Stock Dropped 26.33% on Monday
↗
November 07, 2022
A trial for the company's lead therapy was put on hold.
Via
The Motley Fool
Why Shares Of CRISPR-Focused Verve Therapeutics Just Took A Grim Turn
↗
October 31, 2022
The company is testing a CRISPR-based approach to high cholesterol.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Monday's Intraday Session
↗
November 07, 2022
Gainers
Via
Benzinga
Why Oyster Point Pharma Shares Are Trading Higher By Around 40%? Here Are 49 Stocks Moving In Monday's Mid-Day Session
↗
November 07, 2022
Gainers Dragon Victory International Limited (NASDAQ: LYL) surged 52.2% to $0.6870.
Via
Benzinga
Looking Into Verve Therapeutics's Recent Short Interest
↗
November 07, 2022
Verve Therapeutics's (NASDAQ:VERV) short percent of float has fallen 11.53% since its last report. The company recently reported that it has 10.73 million shares sold short, which is 33.6% of all...
Via
Benzinga
Dow Jumps Over 200 Points; Verve Therapeutics Shares Plummet
↗
November 07, 2022
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 200 points on Monday.
Via
Benzinga
Dow Up Triple Digits Ahead Of Busy Week
↗
November 07, 2022
The Dow Jones Industrial Average is up 212 points midday, continuing Friday's flourish, while the Nasdaq Composite and S&P 500 Index sit more hesitantly in the black.
Via
Talk Markets
IAA Stock Moves as Ritchie Bros Acquires Company in $7.3 Billion Deal
↗
November 07, 2022
IAA (IAA) stock is moving on Monday thanks to a massive acquisition $7.3 billion deal with Ritchie Bros Auctioneers (RBA).
Via
InvestorPlace
Verve Therapeutics Shares Tumble After FDA Hold On Trial For Elevated Cholesterol Level Candidate
↗
November 07, 2022
Via
Benzinga
Why Is Verve Therapeutics (VERV) Stock Down 28% Today?
↗
November 07, 2022
Verve Therapeutics (VERV) stock is taking a beating on Monday following bad news from the U.S. Food and Drug Administration (FDA).
Via
InvestorPlace
TreeHouse Foods, Ritchie Bros. Auctioneers, Beam Therapeutics And Some Other Big Stocks Moving Lower On Monday
↗
November 07, 2022
U.S. stocks traded mostly higher, with the Dow Jones gaining more than 150 points on Monday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
US Stocks Mixed; Dow Rises Over 50 Points
↗
November 07, 2022
U.S. stocks traded mixed this morning, with the Dow Jones gaining over 50 points on Monday.
Via
Benzinga
Verve Crashes After FDA Halts Plan To Test Gene Editor In People
↗
November 07, 2022
Verve Therapeutics hopes to use a next-generation form of CRISPR called base editing.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
November 07, 2022
Gainers Cidara Therapeutics (NASDAQ:CDTX) shares rose 14.6% to $0.64 during Monday's pre-market session. The market value of their outstanding shares is at $44.9 million. The company's, Q3 earnings...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
↗
November 07, 2022
Good morning, investor! We're diving into the biggest pre-market stock movers for Monday as we get ready for another week of trading!
Via
InvestorPlace
Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results
November 07, 2022
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Publication of VERVE-101 Preclinical Data in Circulation and Presentations at the American Heart Association Annual Meeting
October 31, 2022
Verve Researchers Awarded Paul Dudley White International Scholar Award from the American Heart Association for Highest Ranked Abstract Submitted from the United States to Scientific Sessions 2022
From
Verve Therapeutics
Via
GlobeNewswire
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
↗
October 20, 2022
Despite enthusiasm in some camps, the risk of potential cures clouds market projections.
Via
Investor's Business Daily
A Look Into Healthcare Sector Value Stocks
↗
October 10, 2022
What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base...
Via
Benzinga
Verve's Stock Price Could Continue To Rise Through Clinical Progress - Despite Worries About "DeeperPocketed" Competition
↗
October 06, 2022
Via
Benzinga
Cathie Wood Just Bought the TSLA Stock Dip. Should You?
↗
October 04, 2022
Cathie Wood is doubling down on TSLA stock. Here's why investors may want to follow her lead before markets shift in 2023.
Via
InvestorPlace
A Look Into Healthcare Sector Value Stocks
↗
October 03, 2022
The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2022
↗
October 06, 2022
Upgrades
Via
Benzinga
5 Top Stocks Cathie Wood Is Buying This Week
↗
September 30, 2022
There's a new Ark fund in town, and its name is the ARK Venture Fund. It will capitalize on democratizing private investments to the public.
Via
InvestorPlace
Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday
↗
September 28, 2022
Gainers
Via
Benzinga
Why Bellerophon Therapeutics Shares Are Trading Higher By 24%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session
↗
September 27, 2022
Gainers
Via
Benzinga
Amazon, bluebird bio And 3 Stocks To Watch Heading Into Monday
↗
September 26, 2022
With US stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
Cathie Wood Loads Up $23M Worth Of Shares In This Gene-Editing Company As Stock Falls Over 10% In A Month
↗
September 25, 2022
Cathie Wood-led Ark Investment Management on Friday raised its stake in clinical stage genetics medicine company Verve Therapeutics Inc (NASDAQ: VERV) via two of its exchange-traded funds.
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.